Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Eli Lilly And Co (LLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Eli Lilly And Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Eli Lilly And Co trades at $1,183.88 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 26.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Eli Lilly And Co pays a 0.58% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LLY | |
|---|---|---|
Market Cap | $39.89B | $1.06T |
Sector | Health | Health |
52-Week High | $491.22 | $1.24K |
52-Week Low | $278.09 | $625.65 |
Enterprise Value | $38.15B | $1.10T |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Eli Lilly (LLY) trades at $1,188.58, down 2.33% over 24 hours, but maintains a strong technical bullish trend with support near $1,172. The company demonstrates exceptional fundamental strength, with 2025 revenue surging to $65.18B and net income reaching $20.64B, driven by robust demand for its obesity and diabetes drugs. Recent news highlights a $400B market cap surge over the past year and positive analyst coverage, though valuation multiples remain elevated.
Outlook remains positive given Lilly's dominance in high-growth therapeutic areas and consistent earnings beats, but risks include intense competition from Novo Nordisk and rich valuations. Wall Street consensus is strongly bullish with a $1,340 price target, suggesting 13% upside from current levels, supported by institutional confidence in long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
